Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorundrostat in uncontrolled hypertension
NCT05769608Phase 2Completed
- Sponsor
- Mineralys Therapeutics
- Start
- Mar 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lorundrostat in hypertension (HTN), sponsored by Mineralys Therapeutics. Started Mar 2023; status: completed.
02
Drugs
lorundrostat
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05769608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05769608.